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Abstract
Most cancer related deaths are due to the development of metastatic disease and several new
molecularly targeted agents in clinical development have the potential to prevent disease
progression. However, it remains difficult to assess the efficacy of anti-metastatic agents in the
clinical setting and an increased understanding of how such agents work at different stages of the
metastatic cascade is important in guiding their clinical use. We have used optical window
chambers combined with the use of photobleaching, photoactivation, and photoswitching to
quantitatively measure a) tumor cell movement and proliferation by tracking small groups of cells
in the context of the whole tumor, and b) E-cadherin molecular dynamics in vivo following
perturbation of integrin signaling by inhibiting focal adhesion kinase (FAK) and Src. We show
that inhibition of Src and FAK suppresses E-cadherin dependent collective cell movement in a
complex 3D tumor environment, and modulate cell-cell adhesion strength and endocytosis in
vitro. This demonstrates a novel role for integrin signaling in the regulation of E-cadherin
internalization, which is linked to regulation of collective cancer cell movement. This work
highlights the power of fluorescent, direct, in vivo imaging approaches in the pre-clinical
evaluation of chemotherapeutic agents, and shows that inhibition of the Src/FAK signaling axis
may provide a strategy to prevent tumor cell spread by de-regulating E-cadherin-mediated cell-cell
adhesions.
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Introduction
In their physiological environment, cells are in contact with surrounding extracellular matrix
(ECM) and with neighbouring cells. While cell–matrix adhesions are largely integrin-based,
cell–cell junctions are mediated by AJs, tight junctions and desmosomes. Cadherin-based
AJs provide the initial means of cell–cell contact and have key roles during development
and maintenance of epithelial polarity (1, 2). Additionally, there is overwhelming evidence
that E-cadherin is an important tumor and/or invasion suppressor (3-5). Tumor cells employ
a number of strategies to move in vivo; either as individual cells or collectively as cohesive
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groups of cells which maintain cell-cell contacts (6). However, many tumors can adapt their
mode of movement in response to external stimuli and several lines of evidence support the
idea of cross-talk between integrin-mediated cell-ECM interactions and E-cadherin-
mediated cell-cell junctions which may be key to the plasticity observed in tumor cells (7,
8). Although the mechanisms involved are not understood integrin-dependent modulation of
Rho GTPases and the actomyosin cytoskeleton which is tethered at both adhesion types,
may play an important role (9). In addition, Src and focal adhesion kinase (FAK), two non-
receptor tyrosine kinases, which are key regulators of integrin dependent matrix adhesions,
have been linked to the control of AJs. Upon integrin engagement both FAK and Src
tyrosine kinases are autophosphorylated on specific tyrosine residues at integrin-mediated
adhesions. FAK autophosphorylation on Y397 creates a high affinity binding site for the
SH2 domain of Src which leads to the Src-dependent phosphorylation of FAK on additional
tyrosine residues. These act as protein-protein interaction motifs and link the FAK-Src
complex to a number of downstream signaling pathways (10). Increased Src activity is
associated with the disruption of E-cadherin dependent AJs and this was shown to be
dependent on integrin signalling and FAK phosphorylation indicating that the Src/FAK
signalling axis may play an important role in the cross-talk between integrin- and E-
cadherin-dependent adhesions (7).
Most cancer related deaths are due to the development of metastatic disease and several new
molecularly targeted agents in clinical development (including those targeting both Src and
FAK) have the potential to prevent disease progression (11). However, it remains difficult to
assess the efficacy of anti-metastatic agents in the clinical setting and an increased
understanding of how such agents work at different stages of the metastatic cascade is
important in guiding their clinical use. As the tumor microenvironment plays a key role in
disease progression (12) it is becoming evident that the use of appropriate animal models is
essential for determining the activity of such agents. In order for cells to metastasize to
distant sites they must undergo a number of phenotypic changes including changes in cell-
matrix and cell-cell adhesions, migration and invasive capacity but these have been difficult
to monitor in vivo. Here we describe the use of optical window chambers in combination
with photobleaching, photoactivation and photoswitching to quantitatively measure
collective tumor cell movement, proliferation and protein dynamics in squamous cell
carcinoma cells within a tumor mass in vivo. We demonstrate that inhibiting the Src/FAK
signaling axis prevents the collective movement of tumor cells in vitro and in vivo, and
identify a novel role for this pathway in the regulation of E-cadherin internalization, cell-cell
adhesion strength, and modulation of E-cadherin dynamics downstream of β1-integrin.
Taken together this data highlights the benefits of fluorescent in vivo imaging approaches
together with the use of optical window chambers in the pre-clinical evaluation of potential
chemotherapeutic agents, and suggests that the anti-invasive properties of small molecular
inhibitors targeting Src and FAK may be mediated in part by their ability to regulate cell-cell
adhesion.
Materials and Methods
Cell culture
A431 cells (LGC Promochem) were transfected with GFP-E-cadherin (13), pDendra2
(Evrogen), nuclear photoactivatable Green Cherry (nGPAC) (14) or Y527F Src-GFP (15)
using the Amaxa nucleofector transfection system (Amaxa GmbH). Cells stably expressing
siRNA against β1-integrin and their corresponding control cells were a kind gift from Erik
Sahai (16). For siRNA experiments cells were transfected with 50 nM of E-cadherin or FAK
siRNA smartpool or siCONTROL pool1 (Dharmacon) using the Amaxa nucleofector
transfection system. The following treatments were used: β1 blocking Ab, clone mAb13
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(17) 2 μg/ml, 1 - 3 h; dynasore (Sigma) 80 μM, 0.5 - 2 h; PF-562,271 (Pfizer), 250 nM, 1 -
72 h; dasatinib (Bristol Myers Squibb) 200 nM, 1 – 72 h.
Collagen invasion assays
Cells were seeded on the bottom of transwell inserts (Corning) containing rat tail collagen
type I (Roche). Transwell inserts were then placed in serum-free medium, and medium
supplemented with 10% FCS and 10 ng/ml EGF was placed on top of the gel. After 5 days,
cells were stained with Calcein AM (Molecular Probes). Horizontal z-sections through the
gel were taken at 10 μm intervals using an Olympus FV1000 confocal microscope. The
number of positive pixels in each image was determined using ‘Image J’ software (NIH).
The values obtained for individual sections were normalized over the sum of values for all
the sections and then expressed as a percentage of the control cell value. For each
experiment, samples were run in triplicate and at least four z-series were taken per sample.
Projected images used for display purposes were also created using ‘Image J’.
Dispase-based dissociation assay
Quantification of adhesion strength following mechanical stress of dispase treated
monolayers was determined as previously described (18).
Surgical Implantation of Optical Window Chambers
Optical window chambers were implanted into CD-1 nude mice under anaesthesia. All
animal work was carried out in compliance with UK Home Office guidelines. Optical
window chambers were custom fabricated using aluminum (19). To install the window
dorsal skin was sutured to a c-clamp template. A circle of skin was removed and screw holes
made using a 2 mm biopsy punch. The frame of the window chamber was then fitted to
either side of the skin-flap and secured using screwing nuts; the tightness of which was
adjusted to ensure that blood vessels were not occluded. The window was then sutured to the
skin and the c-clamp removed. A small piece of tumor was placed into the centre of the
window and sealed with a coverslip. Tumors were allowed to establish under the windows
for 10 days prior to imaging at which time there was extensive re-vascularization (Figure
S1A,B, Movie S1). Further details on the optical window chambers are provided in
Supplementary Methods.
Immunoblot analysis
Immunoblot analysis was performed as previously described (20). Primary antibodies used
were anti-GFP (Abcam), anti-E-cadherin, anti-FAK (Becton Dickinson Transduction
Laboratories), anti-pY397 FAK, anti-pY861 FAK (Biosource), anti-pY416 Src, anti-Src
(Cell Signaling), β1-integrin (Chemicon) and anti-γ-tubulin (Sigma) all at 1:1000 dilution.
FRAP analysis
For in vitro measurements cells were maintained at 37°C in a temperature controlled
chamber while animals were maintained at 37°C on a heated stage for in vivo
measurements. Experiments were performed using an Olympus FV1000 confocal
microscope with SIM scanner. For photobleaching the following settings were used: pixel
dwell time 4 μs/px, pixel resolution 512 × 512, 5% 488 nm laser power (30% for in vivo)
488 nm laser power, pinhole 250 μm, 60x Oil 1.35 N.A. objective (40× water 0.8 N.A. for
in vivo), and a 3× zoom. Effective photobleaching was achieved using 50% (40% for in
vivo) 405 nm laser power, 20 μs/pixel (40 μs/pixel for in vivo) dwell time, and a 1 frame (3
frames for in vivo) bleach time. Images were captured every 5 sec for 75 frames (100 frames
for in vivo). For in vitro experiments, approximately 25 cells were imaged over 3
independent experiments, and for in vivo experiments 5 animals were imaged per condition
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with 6 movies captured from each animal. Mice were treated with PF-562,271 (33 mg/kg in
0.5% methylcellulose, p.o. by gavage) 30 minutes prior to imaging. Fluorescent intensity
measurements derived from the region of interest used to bleach were averaged in Excel and
used to plot recovery / decay curves. Average measurements for each time-point were
exported into SigmaPlot (Systat Inc) for exponential curve fitting. The half-time of recovery
(t1/2) was calculated as described previously (21).
In vivo photoswitching
Dendra2 expressing tumors were implanted in optical window chambers and imaged at 0, 6
and 24 hours after photoswitching. All images were captured using an Olympus FV1000
confocal microscope equipped with a UMPLFLN 20× 0.5 N.A. water immersion objective.
Photo-switching of Dendra2 was achieved using the following settings: pixel dwell time 40
μs/px, 28% 405 nm laser power, 5 frame switching time. Mice were treated with
PF-562,271 (33 mg/kg in 0.5% methylcellulose, p.o. by gavage BID) or dasatinib (15 mg/kg
in 80 mM citrate buffer, p.o. by gavage qd) starting on the day of photoswitching. After
photoswitching a region of interest, a z-series was acquired (sections every 10 μm) for both
green and red channels. Image analysis was performed using ImageJ. Each z-series was
flattened into one image using the maximum z-intensity projection tool, thresholded, and the
area occupied by the red fluorescent channel measured. This area was plotted over time as a
fold increase in area occupied by migrating cells.
Endocytosis of E-cadherin
Quantification of biotinylated E-cadherin endocytosis was performed as described
previously (18).
Further experimental details are given in S1 Text.
Results
FAK and Src regulate A431 collective cell movement in vitro and in vivo
We have previously demonstrated that A431 cells invade in a collective manner in vitro
which is dependent on the presence of E-cadherin dependent AJs (20). Treatment of cells
with either the FAK inhibitor PF-562,271 or the Src inhibitor dasatinib resulted in complete
inhibition of collective cell invasion into collagen (Figure 1A), at a concentration where
FAK kinase activity (as measured by FAK autophosphorylation on Y397) and Src activity
(as measured by Src autophosphorylation at Y416) were inhibited respectively (Figure 1B).
Treatment of cells with dasatinib also inhibited the Src-dependent phosphorylation of FAK
on Y861 (Figure 1B). To enable imaging and quantification of tumor cell movement in vivo,
cells were transfected with the photoswitchable probe Dendra2 and tumors established under
observation windows (Figure S1A)(22). A subpopulation of tumor cells were marked by
switching Dendra2 from its green to red emitting state and z-sections acquired over 24 hours
(Figure 1C) and cell movement quantified by calculation of the fold increase in area of the
red fluorescence (Figure 1D). There was extensive movement of the tumor cells over 24
hours in the vehicle treated animals which was inhibited in both dasatinib and PF-562,271
treated animals (Figure 1C, D). Similar studies were carried out in cells at the edge of the
tumors. Although A431 Dendra2 cells dispersed over time we rarely detected any cells
moving away from the original tumor area into the surrounding stroma within the time
frame of our experiments (Figure S2) and could therefore not use this approach to follow the
invasion of the A431 cells into the surrounding stroma.
While observation of A431 cell behavior in vivo indicated extensive cell movement, our
results did not rule out the possible contribution of increased cell proliferation/survival to the
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fold increase in area being measured. To address the contribution of proliferation and/or
survival, A431 cells were transfected with a nuclear targeted photoactivatable GFP fused to
mCherry (nGPAC) (14). A subpopulation of tumor cells were marked by activation of the
nuclear targeted photoactivatable GFP and a confocal z-series acquired over 24 hours
(Figure S3A). 3-dimensional rendering and spot detection of photoactivatable GFP marked
nuclei (Figure S3B) was used to quantify the number of nuclei at each time point, and
calculate the fold change in nuclear number (Figure S3C). There was a 1.2 fold increase in
nuclear number over 24 hours, which was unchanged following PF-562,271 treatment. This
increase in nuclear number was used to normalize measurements from Figure 1D (Figure
S3D). Thus FAK kinase activity does not contribute to the proliferation/survival of A431
cells in vivo in the time scale of this experiment, and furthermore the basal level of tumor
cell proliferation was not sufficient to account for the fold increase in area measured
following photoswitching.
E-cadherin modulates collective movement of A431 cells in vitro and in vivo
We have previously reported that loss of E-cadherin at sites of cell-cell adhesion inhibits
collective invasion of A431 cells in vitro (20). However, over-expression of E-cadherin (2.3
fold increase, Figure S4A) also inhibited invasion of A431 cells into collagen (Figure 2A),
suggesting that a balance exists between E-cadherin expression and collective invasive
capacity. To address whether E-cadherin over-expression affected tumor cell movement in
vivo, cells were labeled with Dendra2 and tumors established under observation windows.
In contrast to control tumors, cells over-expressing E-cadherin exhibited a marked reduction
in motility (Figure 2B, C). Furthermore, visual observation of acquired images revealed that
A431 cells maintain their collective mode of migration in vivo (Figure 2D, (*) indicates
individual cells within groups), suggesting that these cells are also dependent on E-cadherin
mediated cell-cell adhesions for their movement in vivo.
FAK signaling regulates E-cadherin dynamics in vitro and in vivo
We have recently demonstrated that the use of fluorescence recovery after photobleaching
(FRAP) allows us to monitor E-cadherin dynamics both in vitro and in vivo (21). Changes in
the recovery rate of E-cadherin molecules are associated with increased migratory potential
of cells. For example the recovery rate of GFP-E-cadherin following photobleaching in
migrating cells is slower than in stationary cells, while inhibition of Src signaling, which
reduces cell migration increases the recovery rate of GFP-E-cadherin (21). Here we set out
to determine whether changes in E-cadherin dynamics were also seen following inhibition of
FAK kinase activity. GFP-E-cadherin at sites of cell-cell adhesion was subjected to
photobleaching (Figure 3A, Movie S2 and S3). Recovery kinetics data for GFP-E-cadherin
± PF-562,271 treatment was pooled and fitted to single exponential rise-to-maximum curves
(Figure S5A). R2 values reflected the tight fit of our data to the predicted values (Control/
PF-562,271, R2 = 0.98). Treatment of cells with PF-562,271 decreased the half-time of
recovery (t1/2) by 40%. To confirm these effects were specific to inhibition of FAK kinase
activity we also used siRNA to knock-down FAK expression (Fig. S4B). A similar reduction
in t1/2 was seen in FAK knock-down cells (Figure 3B). As FAK is an important downstream
effector of integrin signaling we carried out FRAP of GFP-E-cadherin in cells expressing
β1-integrin siRNA in which there was a specific knock-down of β1-integrin protein
expression (Figure S4C) and also saw a reduction in the t1/2 (Figure 3B). These results
identify β1-integrin and its downstream effector FAK as key regulators of E-cadherin
dynamics and that inhibition of E-cadherin dependent collective movement correlates with
an increased rate of recovery of GFP-E-cadherin.
We next asked whether changes in E-cadherin dynamics could also be used as a read-out of
E-cadherin function in vivo. Tumors expressing GFP-E-cadherin were established under
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observation windows and GFP-E-cadherin at sites of cell-cell adhesion subjected to
photobleaching (Figure 3C, Movie S4 and S5). Recovery kinetics data for GFP-E-cadherin
in either vehicle or PF-562,271 treated animals was pooled and fitted to single exponential
rise-to-maximum curves (Figure S5B). R2 values reflected the tight fit of our data to the
predicted values (Control/ PF-562,271, R2 = 0.97). Treatment of animals with PF-562,271
prior to photobleaching of GFP-E-cadherin resulted in a marked reduction in the t1/2
(Control, 38.3 ± 3.2 seconds; PF-562,271, 20.4 ± 2.5 seconds; Figure 3D); similar to that
observed in vitro. Thus inhibition of FAK kinase activity following treatment with
PF-562,271 results in altered E-cadherin dynamics in vivo, which correlates with reduced E-
cadherin-dependent collective cell movement.
FAK controls E-cadherin internalization and cell-cell adhesion strength downstream of β1-
integrin
The observation that E-cadherin over-expression and inhibition of Src/FAK signaling both
resulted in inhibition of invasion and the ability of Src/FAK to regulate E-cadherin dynamics
both in vitro and in vivo, led us to hypothesize that inhibiting the Src/FAK signaling axis
may regulate the collective movement of A431 cells via regulation of E-cadherin. It has
been previously reported that the level of E-cadherin protein at sites of cell-cell adhesion
regulates cadherin adhesiveness (23), therefore we hypothesized that increased E-cadherin
expression at these sites may inhibit cell movement by increasing cell-cell adhesion strength.
To determine the effect of E-cadherin expression on cell-cell adhesion strength we treated
confluent cultures with dispase which results in detachment of the cells in an intact
monolayer. The resistance to disaggregation induced by mechanical stress of these
monolayers is then used as a measure of the relative strength of cell-cell contacts. Over-
expression of E-cadherin resulted in a reduction in the number of single cells detached from
the cell sheets, while inhibition of E-cadherin expression by siRNA decreased adhesion
strength (Figure 4A), indicating a crucial role for E-cadherin in A431 cell-cell adhesion
strength. Treatment of cells with PF-562,271 or knock-down of FAK by siRNA was also
observed to increase cell-cell adhesion strength (Figure 4A). Furthermore, inhibition of Src
kinase activity by dasatinib increased cell-cell adhesion strength (Figure 4A). However, this
was not mediated by increased expression of E-cadherin in the inhibitor treated cells (Figure
S6).
To explore the signalling events taking place upon β1-integrin inhibition, we looked at
activation of both FAK and Src in β1-integrin siRNA expressing cells. Using vinculin as a
marker of integrin adhesions, activation of both Src and FAK in control cells was detected in
integrin adhesions (Figure S4D). However, in cells lacking β1-integrin, although FAK was
active at integrin adhesions (as measured by pY397 FAK), active Src was absent and
furthermore there was no detectable pY861 FAK (Figure S4D). Thus cells lacking β1-
integrin are still able to assemble cell-matrix adhesions which contain active FAK. This may
be due to incomplete knock down of β1-integrin in the cells or signalling to Y397 FAK from
other β-integrin sub-units (16). However, active Src was absent from these adhesions and
therefore unable to phosphorylate FAK. Disruption of β1-integrin signalling therefore
specifically prevents activation of Src at integrin adhesion sites. In contrast, active Src was
still present at integrin adhesion sites in FAK knock down cells (Figure S4E), while the
amount of activated Src bound to FAK in wild type cells was decreased in the presence of
PF-562,271, as detected by immunoprecipitation (Figure S4F). Thus molecular
characterisation of signalling through Src and FAK in both FAK and β1-integrin knockdown
cells highlighted a single common event: suppression of Src-dependent phosphorylation of
FAK at integrin adhesions (either mediated via loss of activated Src from integrin adhesions
(as seen in β1-integrin knockdown cells) or its inability to bind to FAK either through loss
of FAK protein (as seen in FAK knockdown cells) or kinase inhibition (PF-562,271 treated
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cells)). Taken together with the ability of dasatinib to prevent phosphorylation of FAK on
Y861, this suggests that the observed effects on E-cadherin and adhesion strength may be
mediated via the Src-dependent phosphorylation of FAK.
To confirm that the ability of Src and FAK to regulate E-cadherin-dependent AJs required
the Src-dependent phosphorylation of FAK downstream of β1-integrin signaling we
expressed a constitutively active Src mutant (Y527F Src) in A431 cells. Western blotting
showed that activated Src and pY861 FAK were increased in cells expressing Y527F Src
(Figure S4G). Constitutive activation of Src resulted in a weakening of cell-cell adhesions as
measured by an increase in single cells following mechanical disruption (Figure 4B) without
causing complete dissolution of cell-cell junctions (Figure S4H). Treatment with a β1-
integrin blocking antibody decreased the number of single cells in control cultures but had
no effect in cells expressing activated Src (Figure 4B). Thus strengthening of cell-cell
junctions following inhibition of β1-integrin is prevented when Src is constitutively active
indicating that expression of an un-regulated active Src negates the ability of β1-integrin to
control adhesion strength. Furthermore, treatment of cells with dasatinib prevented
phosphorylation of FAK on Y861 and increased adhesion strength (Figure 1B and 4A)
indicating that Src-dependent phosphorylation of FAK downstream of β1-integrin regulates
adhesion strength.
As treatment with PF-562,271 or dasatinib did not alter total E-cadherin protein levels
(Figure S6) Src/FAK signaling must regulate E-cadherin function by other mechanisms. E-
cadherin-mediated cell-cell junctions are highly dynamic structures and the concentration of
E-cadherin specifically at cell-cell junctions is controlled by endocytosis which in turn
regulates adhesion strength. To measure endocytosis we followed the internalization of
biotinylated cell surface E-cadherin: biotinylated cell surface E-cadherin was progressively
enriched in the intracellular pool in control cells while in cells treated with dynasore, a
potent dynamin inhibitor that blocks vesicles pinching off the membrane (24), there was no
internalization of E-cadherin (Figure 4C). E-cadherin internalization was reduced in β1-
integrin siRNA cells (Figure 4C). A similar reduction in E-cadherin internalization was seen
in cells treated with dasatinib or when FAK expression was knocked down (Figure 4C).
In support of a link between E-cadherin internalization and adhesion strength, treatment of
cells with dynasore also increased adhesion strength (Figure 4A). Furthermore, FRAP
analysis of dynasore treated cells showed a reduction in the t1/2 of GFP-E-cadherin as was
seen following inhibition of Src/FAK signaling (Figure 4D). Thus although measurement of
E-cadherin-mediated cell-cell adhesion strength and E-cadherin internalization is not
possible in vivo, changes in the t1/2 may represent an indirect read-out of E-cadherin
function that can be measured in vivo.
Discussion
We have identified a novel role for Src and FAK in regulating E-cadherin function which is
required for the collective movement of tumor cells. In human tumors loss of E-cadherin is
associated with more aggressive and invasive tumors. However, it is now evident that the
collective movement of tumors, which is dependent on the maintenance of cell-cell
junctions, also plays a key role in the invasive capacity of tumors (6). A tight balance exists
between E-cadherin expression and collective movement and the dynamic regulation of E-
cadherin at cell-cell junctions is crucial in determining junction strength which we have
previously linked to the migratory capacity of tumor cells in vitro (21). Here we demonstrate
that Src/FAK signaling downstream of β1-integrin controls E-cadherin internalization and
adhesion strength in vitro. Functional measurements of E-cadherin mediated cell-cell
adhesion strength and E-cadherin internalization are not currently possible in vivo and it is
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therefore important to utilize techniques such as FRAP to monitor E-cadherin dynamics
which can provide an indirect read-out of E-cadherin function which would otherwise not be
possible in vivo. The ability of small molecule inhibitors of Src and FAK to alter E-cadherin
dynamics in vivo correlated with their ability to strengthen cell-cell adhesion, inhibit E-
cadherin internalization and importantly inhibit the collective movement of A431 cells in
vivo. Src and FAK can regulate cell invasion in vitro through its role in regulating cell
migration and matrix metalloproteinase activity at sites of invadopodia (25-29). These
findings identify a novel additional mechanism through which β1-integrin signaling via Src
dependent phosphorylation of FAK may regulate the collective movement of tumor cells by
modulating cell-cell adhesion strength through control of E-cadherin internalization.
Previously the use of skin flaps has been used to monitor the movement of tumor cells in
vivo but these studies are restricted by the short period of time that migration can be
monitored over and the infrequency that individual cells move in vivo within these time
frames. To overcome these problems we have utilized optical window chambers, which
together with recoverable anesthesia, enabled the repeated imaging of animals over several
days. In addition, in contrast to skin flaps, observation windows do not require invasive
surgery immediately prior to imaging, and therefore preserve the local tumor
microenvironment by minimizing the risk of inflammatory response and tissue damage as a
consequence of surgery. Furthermore, images acquired using this method displayed
improved signal to noise and increased sample stability, when compared to our previously
reported use of skin flaps for FRAP (21). A comparison of FRAP data acquired in vivo
using skin flaps and optical window imaging methods is shown in Figure S5C,D. The
resulting FRAP dataset obtained through the observation windows exhibited R2 values
comparable with those only previously possible in vitro. To enable the imaging and
quantification of tumor cell movement in vivo we combined the implantation of observation
windows with the specific labeling of tumor cells using the photoswitchable protein
Dendra2, in a similar manner to that recently reported by Kedrin and colleagues (22).
Photoswitching of Dendra2 from its green to red emitting state permitted long-term
monitoring of tumor cell behavior. In addition, use of the nuclear targeted photoactivatable
probe GPAC (14) enabled the quantification of nuclear division in vivo. Thus the use of
photoswitchable and photoactivatable probes, together with recoverable imaging using
optical window chambers, can be used to implement robust and reproducible assays for
monitoring the movement and proliferation of tumor cells in vivo and provide invaluable
information regarding drug action which can help to dissect out the mechanism of action of
new therapeutics.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
PF-562,271 and dasatinib inhibit collective cell movement in vitro and in vivo. (A) Invasion
of A431 cells into collagen gels in the presence or absence of PF-562,271 or dasatinib. After
5 days, cells were labeled with calcein AM and visualized at 10 μm intervals. The
experiment was performed in triplicate and representative series of z-sections at indicated
depths through the gel are shown. Scale bars: 200 μm. (B) Immunoblot analysis of pY397
FAK and FAK expression in control and PF-562,271 treated cells and pY416 Src, Src,
pY861 FAK and FAK in control and dasatinib treated cells. (C) Images showing A431
Dendra2 control expressing cells in tumors of untreated mice or mice treated with
PF-562,271 or dasatinib, at different time points after photoswitching (red). Scale bars: 100
μm. (D) Quantification of the area covered by red fluorescence at shown time points. Values
are the mean from at least 5 independent experiments. Error bars: s.e.m.
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Figure 2.
E-cadherin modulates collective cell movement in vitro and in vivo. (A) Invasion of A431
and A431 GFP-E-cadherin cells into collagen gels. After 5 days, cells were labeled with
calcein AM and visualized at 10 μm intervals. Representative series of z-sections at
indicated depths through the gel are shown. Scale bars: 200 μm. Quantification of invasion
at 80 μm is shown for a representative experiment in a series of three. Values are the mean
from triplicate wells. (B) Images showing A431 Dendra2 control or GFP-E-cadherin
expressing cells in tumors at different time points after photoswitching (red). Scale bars: 100
μm. (C) Quantification of the area covered by red fluorescence at shown time points. Values
are the mean from at least 5 independent experiments. (A, C) Error bars: s.e.m. (D) Zoomed
images from (B) (left panel) and higher magnification images (centre and right panels)
showing collective cell movement where individual cells within a group are marked by (*).
Scale bars: 20 μm (left and centre images), 10 μm (right image).
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Figure 3.
PF-562,271 alters E-cadherin dynamics in vitro and in vivo. (A) Still images of GFP-E-
cadherin at cell-cell junctions in cells untreated (top panels) or treated with PF-562,271
(bottom panels) captured pre-bleach and following bleach. Scale bar: 5 μm. Arrows indicate
bleached area (B) t1/2 of GFP-E-cadherin in control cells or cells treated with PF-562,271,
FAK siRNA or β1-integrin blocking antibody. (C) Still images of GFP-E-cadherin at cell-
cell junctions in tumors untreated (top panels) or treated with PF-562,271 (bottom panels)
captured pre-bleach and following bleach. Arrows indicate bleached areas (D) t1/2 of GFP-
E-cadherin in tumors from control or PF-562,271 treated mice. (A, C) Scale bars: 5 μm. (B,
D) Values are the mean from at least 25 cells. Error bars: s.e.m.
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Figure 4.
Inhibition of Src-dependent phosphorylation of FAK downstream of β1-integrin disrupts E-
cadherin endocytosis and strengthens cell-cell junctions. (A) Number of single cells that
disaggregate from a dispase treated monolayer. Values represent the mean from at least
three independent experiments. (B) Number of single cells that disaggregate from a dispase
treated monolayer in control and Y527F Src expressing cells in the presence or absence of
β1-integrin blocking antibody or dasatinib. Values represent the mean from at least three
independent experiments. (C) Quantification of biotinylated E-cadherin internalization over
10 min in control or FAK siRNA cells, β1-integrin siRNA cells, control cells treated with
dasatinib or dynasore. (D) t1/2 of GFP-E-cadherin in control or dynasore treated cells.
Values are the mean from at least 25 cells. (A, B, D) Error bars: s.e.m.
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